Natalizumab: a guide to its use in relapsing–remitting multiple sclerosis
The humanized monoclonal antibody natalizumab (Tysabri®) is the first targeted therapy to be approved for the treatment of relapsing–remitting multiple sclerosis (RRMS). The annualized relapse rate, the risk of sustained progression of disability and the number of T2-hyperintense and gadolinium-enhancing lesions on magnetic resonance imaging were significantly lower with intravenous natalizumab than with placebo at 2 years in patients with RRMS in a phase III trial. In addition, treatment with natalizumab was generally associated with improved health-related quality of life and was well tolerated. Progressive multifocal leukoencephalopathy (PML) is an uncommon complication of treatment with natalizumab. As long as the risk of PML is managed effectively, natalizumab is a valuable therapeutic option for adults with highly active relapsing forms of MS.
- 4.Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169–78.PubMedCrossRefGoogle Scholar
- 5.Tysabri (natalizumab) concentrate for solution for infusion: EU summary of product characteristics. London: European Medicines Agency; 2013.Google Scholar
- 9.Olofsson S, Wickstrom A, Hager Glenngard A, et al. Effect of treatment with natalizumab on ability to work in people with multiple sclerosis: productivity gain based on direct measurement of work capacity before and after 1 year of treatment. Biodrugs. 2011;25(5):299–306.Google Scholar
- 11.Goodman A, O’Connor P, Polman C, et al. Updated safety and efficacy of natalizumab in the ongoing STRATA study [abstract]. Mult Scler. 2011;17(10 Suppl 1):S444–5.Google Scholar
- 12.Polman C, Goodman A, Kappos L, et al. Efficacy and safety of natalizumab in the STRATA study [abstract no. P06.173]. In: 62nd annual meeting of the American Academy of Neurology, 10–17 Apr 2010, Toronto (ON).Google Scholar
- 13.Kappos L, Belachew S, Butzkueven H, et al. Long-term safety and efficacy and association between baseline treatment history and postbaseline relapses in multiple sclerosis patients treatment with natalizumab in the Tysabri® observational program (TOP) [abstract no. P04.134]. Neurology. 2012;78(Suppl).Google Scholar
- 14.Panzara MA, Bozic C, Sandrock AW. More on melanoma with transdifferentiation. N Engl J Med. 2008;359(1):99 (author reply 100).Google Scholar
- 16.Barts and The London School of Medicine and Dentistry. Mulitple sclerosis research: natalizumab PML update: September 2013. 2013. http://multiple-sclerosis-research.blogspot.co.nz/2013/10/natalizumab-pml-update-september-2013.html. Accessed 29 Nov 2013.
- 17.Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JCV antibody index further defines PML risk in natalizuamb-treated MS patients [poster]. In: 27th annual meeting of the Consortium of Multiple Sclerosis Centers; 29 May to 1 Jun 2013, Orlando (FL).Google Scholar
- 18.Plavina T, Subramanyam M, Bloomgren G, et al. Use of JV virus antibody index to stratify risk of progressive multifocal leukoencephalopathy in natalizumab-treated patients with multiple sclerosis [abstract no. O228]. J Neurol. 2013;260(Suppl 1):S13.Google Scholar